ab521
Small moleculeexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Nov 4, 2021 (NCT05117554)
Timeline
Indications
Mechanism of action
EPAS1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068220 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07011719 | Phase 3 | Sep 8, 2025 | Arcus Biosciences, Inc. |
| NCT07000149 | Phase 3 | Jul 28, 2025 | Arcus Biosciences, Inc., AstraZeneca |
| NCT06919991 | Phase 1 | May 2, 2025 | Arcus Biosciences, Inc. |
| NCT06191796 | Phase 1/Phase 2 (Phase 2) | Jan 25, 2024 | Arcus Biosciences, Inc., Exelixis |
| NCT05999513 | Phase 1 | Aug 21, 2023 | Arcus Biosciences, Inc. |
| NCT05536141 | Phase 1 | Oct 26, 2022 | Arcus Biosciences, Inc. |
| NCT05117554 | Phase 1 | Nov 4, 2021 | Arcus Biosciences, Inc. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arcus Biosciences, Inc. | For profit | 7 | 5 | 3 | 2021 |
| AstraZeneca | For profit | 1 | 1 | 1 | 2025 |
| Exelixis | For profit | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1